These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28330604)

  • 21. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
    Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
    Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
    Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
    Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor specific novel taxoid-monoclonal antibody conjugates.
    Wu X; Ojima I
    Curr Med Chem; 2004 Feb; 11(4):429-38. PubMed ID: 14965224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Site-Specific Lysine Arylation as an Alternative Bioconjugation Strategy for Chemically Programmed Antibodies and Antibody-Drug Conjugates.
    Hwang D; Tsuji K; Park H; Burke TR; Rader C
    Bioconjug Chem; 2019 Nov; 30(11):2889-2896. PubMed ID: 31675216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization.
    Harper J; Mao S; Strout P; Kamal A
    Methods Mol Biol; 2013; 1045():41-9. PubMed ID: 23913140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues.
    Lyon RP; Meyer DL; Setter JR; Senter PD
    Methods Enzymol; 2012; 502():123-38. PubMed ID: 22208984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in the construction of antibody-drug conjugates.
    Chudasama V; Maruani A; Caddick S
    Nat Chem; 2016 Feb; 8(2):114-9. PubMed ID: 26791893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
    Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
    Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
    Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
    Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
    Niculescu-Duvaz I
    Curr Opin Mol Ther; 2010 Jun; 12(3):350-60. PubMed ID: 20521224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
    Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.
    Papachristos A; Pippa N; Demetzos C; Sivolapenko G
    Drug Deliv; 2016 Jun; 23(5):1662-6. PubMed ID: 25625494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis of precision antibody conjugates using proximity-induced chemistry.
    Cao YJ; Yu C; Wu KL; Wang X; Liu D; Tian Z; Zhao L; Qi X; Loredo A; Chung A; Xiao H
    Theranostics; 2021; 11(18):9107-9117. PubMed ID: 34522229
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessment of the radiochemical design of antibodies with a metabolizable linkage for target-selective radioactivity delivery.
    Arano Y; Wakisaka K; Akizawa H; Ono M; Kawai K; Nakayama M; Sakahara H; Konishi J; Saji H
    Bioconjug Chem; 1998; 9(4):497-506. PubMed ID: 9667952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody conjugation via one and two C-terminal selenocysteines.
    Li X; Yang J; Rader C
    Methods; 2014 Jan; 65(1):133-8. PubMed ID: 23756202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides.
    Christie RJ; Fleming R; Bezabeh B; Woods R; Mao S; Harper J; Joseph A; Wang Q; Xu ZQ; Wu H; Gao C; Dimasi N
    J Control Release; 2015 Dec; 220(Pt B):660-70. PubMed ID: 26387744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.
    McDonagh CF; Turcott E; Westendorf L; Webster JB; Alley SC; Kim K; Andreyka J; Stone I; Hamblett KJ; Francisco JA; Carter P
    Protein Eng Des Sel; 2006 Jul; 19(7):299-307. PubMed ID: 16644914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.
    Singh SK; Luisi DL; Pak RH
    Pharm Res; 2015 Nov; 32(11):3541-71. PubMed ID: 25986175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.